Abstract #1510

Quantitative Evaluation of Impaired Neuroenergetics in Parkinson’s Disease and the Treatment Effects of Ursodeoxycholic Acid

Xiao-Hong Zhu¹, Byeong-Yuel Lee¹, Lisa Coles², Abhishek G Sathe², Paul Tuite³, Jim Cloyd², Walter Low⁴, Clifford J. Steer⁵, Chi Chen⁶, and Wei Chen¹

¹CMRR, Department of Radiology, University of Minnesota, Minneapolis, MN, United States, ²Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, United States, ³Department of Neurology, University of Minnesota, Minneapolis, MN, United States, ⁴Department of Neurosurgery, University of Minnesota, Minneapolis, MN, United States, ⁵Departments of Medicine and Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN, United States, ⁶Department of Food Science and Nutrition, University of Minnesota, Minneapolis, MN, United States

Abnormal energy metabolism due to mitochondrial dysfunction is thought to be a major contributor to the progression of Parkinson’s disease (PD). We employed ³¹P MRS-MT technique at 7T to quantify key bioenergetic parameters in the occipital lobe of people with PD (PWPs). Significantly lower intracellular ATP concentrations together with elevated ATPase activity was found in PWPs; suggesting that augmented ATPase enzymatic activity may represent a compensatory mechanism to bioenergetic deficits that occur in PD. The FDA-approved drug, ursodeoxycholic acid (UDCA), shown to have energy-enhancing properties was evaluated for its effect on improving neuroenergetics in PWPs using the ³¹P MRS-MT approach.

This abstract and the presentation materials are available to members only; a login is required.

Join Here